217 related articles for article (PubMed ID: 32527287)
1. Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer.
Baker LA; Holliday H; Roden D; Krisp C; Wu SZ; Junankar S; Serandour AA; Mohammed H; Nair R; Sankaranarayanan G; Law AMK; McFarland A; Simpson PT; Lakhani S; Dodson E; Selinger C; Anderson L; Samimi G; Hacker NF; Lim E; Ormandy CJ; Naylor MJ; Simpson K; Nikolic I; O'Toole S; Kaplan W; Cowley MJ; Carroll JS; Molloy M; Swarbrick A
Breast Cancer Res; 2020 Jun; 22(1):63. PubMed ID: 32527287
[TBL] [Abstract][Full Text] [Related]
2. ID4 controls mammary stem cells and marks breast cancers with a stem cell-like phenotype.
Junankar S; Baker LA; Roden DL; Nair R; Elsworth B; Gallego-Ortega D; Lacaze P; Cazet A; Nikolic I; Teo WS; Yang J; McFarland A; Harvey K; Naylor MJ; Lakhani SR; Simpson PT; Raghavendra A; Saunus J; Madore J; Kaplan W; Ormandy C; Millar EK; O'Toole S; Yun K; Swarbrick A
Nat Commun; 2015 Mar; 6():6548. PubMed ID: 25813983
[TBL] [Abstract][Full Text] [Related]
3. ID4 controls luminal lineage commitment in normal mammary epithelium and inhibits BRCA1 function in basal-like breast cancer.
Baker LA; Holliday H; Swarbrick A
Endocr Relat Cancer; 2016 Sep; 23(9):R381-92. PubMed ID: 27412917
[TBL] [Abstract][Full Text] [Related]
4. High cyclin E1 protein, but not gene amplification, is prognostic for basal-like breast cancer.
Aziz D; Lee C; Chin V; Fernandez KJ; Phan Z; ; ; Waring P; Caldon CE
J Pathol Clin Res; 2022 Jul; 8(4):355-370. PubMed ID: 35384378
[TBL] [Abstract][Full Text] [Related]
5. Hyperactive CDK2 Activity in Basal-like Breast Cancer Imposes a Genome Integrity Liability that Can Be Exploited by Targeting DNA Polymerase ε.
Sviderskiy VO; Blumenberg L; Gorodetsky E; Karakousi TR; Hirsh N; Alvarez SW; Terzi EM; Kaparos E; Whiten GC; Ssebyala S; Tonzi P; Mir H; Neel BG; Huang TT; Adams S; Ruggles KV; Possemato R
Mol Cell; 2020 Nov; 80(4):682-698.e7. PubMed ID: 33152268
[TBL] [Abstract][Full Text] [Related]
6. FOXF2 deficiency promotes epithelial-mesenchymal transition and metastasis of basal-like breast cancer.
Wang QS; Kong PZ; Li XQ; Yang F; Feng YM
Breast Cancer Res; 2015 Feb; 17(1):30. PubMed ID: 25848863
[TBL] [Abstract][Full Text] [Related]
7. Protein expression and methylation of DNA repair genes hMLH1, hMSH2, MGMT and BRCA1 and their correlation with clinicopathological parameters and prognosis in basal-like breast cancer.
Alkam Y; Mitomi H; Nakai K; Himuro T; Saito T; Takahashi M; Arakawa A; Yao T; Saito M
Histopathology; 2013 Nov; 63(5):713-25. PubMed ID: 24004112
[TBL] [Abstract][Full Text] [Related]
8. Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.
de Candia P; Akram M; Benezra R; Brogi E
Hum Pathol; 2006 Aug; 37(8):1032-41. PubMed ID: 16867866
[TBL] [Abstract][Full Text] [Related]
9. miR-342 regulates BRCA1 expression through modulation of ID4 in breast cancer.
Crippa E; Lusa L; De Cecco L; Marchesi E; Calin GA; Radice P; Manoukian S; Peissel B; Daidone MG; Gariboldi M; Pierotti MA
PLoS One; 2014; 9(1):e87039. PubMed ID: 24475217
[TBL] [Abstract][Full Text] [Related]
10. Inhibitor of differentiation 4 (ID4) acts as an inhibitor of ID-1, -2 and -3 and promotes basic helix loop helix (bHLH) E47 DNA binding and transcriptional activity.
Sharma P; Chinaranagari S; Chaudhary J
Biochimie; 2015 May; 112():139-50. PubMed ID: 25778840
[TBL] [Abstract][Full Text] [Related]
11. CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis.
Laine A; Nagelli SG; Farrington C; Butt U; Cvrljevic AN; Vainonen JP; Feringa FM; Grönroos TJ; Gautam P; Khan S; Sihto H; Qiao X; Pavic K; Connolly DC; Kronqvist P; Elo LL; Maurer J; Wennerberg K; Medema RH; Joensuu H; Peuhu E; de Visser K; Narla G; Westermarck J
Cancer Res; 2021 Aug; 81(16):4319-4331. PubMed ID: 34145035
[TBL] [Abstract][Full Text] [Related]
12. Tumoral expression of BRCA1, estrogen receptor alpha and ID4 protein in patients with sporadic breast cancer.
Roldán G; Delgado L; Musé IM
Cancer Biol Ther; 2006 May; 5(5):505-10. PubMed ID: 16582598
[TBL] [Abstract][Full Text] [Related]
13. Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer.
Noetzel E; Veeck J; Niederacher D; Galm O; Horn F; Hartmann A; Knüchel R; Dahl E
BMC Cancer; 2008 May; 8():154. PubMed ID: 18513385
[TBL] [Abstract][Full Text] [Related]
14. CDC42 as an epigenetic regulator of ID4 in triple-negative breast tumors.
Nasif D; Real S; Roqué M; Branham MT
Breast Cancer; 2022 May; 29(3):562-573. PubMed ID: 35094293
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic regulation of ID4 in breast cancer: tumor suppressor or oncogene?
Nasif D; Campoy E; Laurito S; Branham R; Urrutia G; Roqué M; Branham MT
Clin Epigenetics; 2018 Aug; 10(1):111. PubMed ID: 30139383
[TBL] [Abstract][Full Text] [Related]
16. Expression of ID4 protein in breast cancer cells induces reprogramming of tumour-associated macrophages.
Donzelli S; Milano E; Pruszko M; Sacconi A; Masciarelli S; Iosue I; Melucci E; Gallo E; Terrenato I; Mottolese M; Zylicz M; Zylicz A; Fazi F; Blandino G; Fontemaggi G
Breast Cancer Res; 2018 Jun; 20(1):59. PubMed ID: 29921315
[TBL] [Abstract][Full Text] [Related]
17. Inhibitor of DNA Binding 4 (ID4) is highly expressed in human melanoma tissues and may function to restrict normal differentiation of melanoma cells.
Peretz Y; Wu H; Patel S; Bellacosa A; Katz RA
PLoS One; 2015; 10(2):e0116839. PubMed ID: 25642713
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic regulation of ID4 in the determination of the BRCAness phenotype in breast cancer.
Branham MT; Campoy E; Laurito S; Branham R; Urrutia G; Orozco J; Gago F; Urrutia R; Roqué M
Breast Cancer Res Treat; 2016 Jan; 155(1):13-23. PubMed ID: 26610810
[TBL] [Abstract][Full Text] [Related]
19. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.
Fontemaggi G; Dell'Orso S; Trisciuoglio D; Shay T; Melucci E; Fazi F; Terrenato I; Mottolese M; Muti P; Domany E; Del Bufalo D; Strano S; Blandino G
Nat Struct Mol Biol; 2009 Oct; 16(10):1086-93. PubMed ID: 19783986
[TBL] [Abstract][Full Text] [Related]
20. Nuclear translocation of PLSCR1 activates STAT1 signaling in basal-like breast cancer.
Huang P; Liao R; Chen X; Wu X; Li X; Wang Y; Cao Q; Dong C
Theranostics; 2020; 10(10):4644-4658. PubMed ID: 32292520
[No Abstract] [Full Text] [Related]
[Next] [New Search]
